Kanagalingam Suthasenthuran, Ul Haq Zargham, Victory Srinivasan Nishok, Khan Aujala Irfan, Mashat Ghadi D, Hazique Mohammad, Khan Kokab Irfan, Ramesh Prasana, Khan Safeera
Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Medicine and Surgery, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Cureus. 2023 Jan 12;15(1):e33691. doi: 10.7759/cureus.33691. eCollection 2023 Jan.
Current non-small cell lung cancer (NSCLC) treatment consists of various combinations of surgery, chemotherapy, and/or radiation, depending on the tumor stage. Individuals with stage II-IIIa NSCLC undergo surgery, followed by combination chemotherapy containing cisplatin, such as vinorelbine + cisplatin. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib, act by inhibiting any signaling pathway containing the EGFR mutation and inhibiting the growth of NSCLC. TKI is a treatment option in advanced NSCLC, resulting in more prolonged progression-free survival (PFS). This manuscript aims to evaluate the influence of utilizing gefitinib - either alone or in combination with conventional chemotherapeutic drug regimens upon NSCLC patient profile survival parameters. A systematic literature review was conducted across multiple scientific literature repositories. The review was performed using the preferred reporting items for systematic reviews and meta-analyses (PRISMA) 2020. There were six randomized clinical trials (RCT) and five retrospective studies. The overall consensus based on the end outcome of each published journal on the effectiveness of gefitinib as a treatment option for NSCLC indicated that there was a notable difference in overall survival (OS) and progression-free survival (PFS) and disease-free survival (DFS) datasets. Gefitinib use correlated with increased timeframes for multiple patient survival parameters within articles shortlisted in this investigation. However, more comprehensive investigations are required to validate such correlations. Gefitinib did demonstrate the potential to provide beneficial effects and counteract NSCLC within such patients.
目前非小细胞肺癌（NSCLC）的治疗包括根据肿瘤分期进行手术、化疗和/或放疗的各种组合。II - IIIa期NSCLC患者接受手术，随后进行含顺铂的联合化疗，如长春瑞滨 + 顺铂。表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKIs），如吉非替尼，通过抑制任何含有EGFR突变的信号通路来抑制NSCLC的生长。TKI是晚期NSCLC的一种治疗选择，可延长无进展生存期（PFS）。本手稿旨在评估单独使用吉非替尼或与传统化疗药物方案联合使用对NSCLC患者生存参数的影响。在多个科学文献库中进行了系统的文献综述。该综述使用系统评价和荟萃分析的首选报告项目（PRISMA）2020进行。有六项随机临床试验（RCT）和五项回顾性研究。基于各发表期刊关于吉非替尼作为NSCLC治疗选择有效性的最终结果的总体共识表明，总生存期（OS）、无进展生存期（PFS）和无病生存期（DFS）数据集存在显著差异。在本研究入围的文章中，吉非替尼的使用与多个患者生存参数的时间延长相关。然而，需要更全面的研究来验证这种相关性。吉非替尼确实显示出在这类患者中提供有益效果和对抗NSCLC的潜力。
